Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies
This psychometric analysis using the PES100 examined 816 measurements from healthy participants (n=386) across 15 controlled psychedelic studies of LSD, psilocybin, mescaline and DMT. It found that mystical oneness was strongly linked to feelings of luminous light and renewal, and moderately to strongly linked to ego disintegration, with these links increasing with dose.
Authors
- Frederick Barrett
- William Richards
- Nathan Sepeda
Published
Abstract
Mystical dynamics—the notion that mystical oneness may unfold involving ego disintegration, renewal, and luminous light—has been discussed anecdotally by psychedelic researchers and therapists but has not yet been empirically examined in controlled settings. This study investigated the occurrence and dose-dependency of mystical dynamics in healthy participants after administration of psychedelics. A total of 816 mystical-dynamics measurements were collected from 386 participants across 15 studies at two sites: University Hospital Basel (Switzerland) and Johns Hopkins University (USA). Participants received low to high doses of four serotonergic psychedelics: LSD, psilocybin, mescaline, and DMT. Mystical dynamics was assessed using five corresponding constructs from the Psychedelic Experience Scale (PES100): ego disintegration, distress, renewal, luminous light, and mystical (focusing on mystical oneness, the core of mystical experience). We hypothesized strong intercorrelations of mystical oneness with ego disintegration, renewal, and luminous light, and a dose-dependent intensity pattern. Results showed dose-sensitive strong correlations of mystical oneness with luminous light and renewal, and a moderate-to-strong correlation of mystical oneness with ego disintegration. These findings support a broader, dynamic model of mystical experience and offer novel insights relevant to psychedelic-assisted therapy, while acknowledging additional experiential features that may also associate with mystical oneness.
Research Summary of 'Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies'
Blossom's Take
This study provides the largest controlled psychometric mapping to date of how mystical oneness, ego disintegration, distress, and experiences of renewal and luminous light relate to one another across classic psychedelics. By showing that ego disintegration sits at the centre of these dynamics, connected to both distress and the mystical-rebirth cluster, the findings reframe ego dissolution not as a mere side effect but as a potential gateway experience that can feed into either difficult or meaningful outcomes. The dose-dependent strengthening of these links, combined with the disappearance of the mystical-distress association once shared variance is controlled for, offers clinicians and researchers a more nuanced model for understanding which experiential components actually drive therapeutic or transformative outcomes under psychedelics.
Introduction
Psychedelic research has documented mystical-type experiences fairly well, particularly experiences of oneness, but the authors note that a broader experiential pattern they call mystical dynamics has mostly been described anecdotally. This pattern refers to mystical oneness unfolding alongside experiences of ego disintegration, renewal or rebirth, and luminous light. The paper also situates this idea within long-standing scholarly and clinical descriptions of psychedelic “death-rebirth” experiences, while noting that the core mystical construct used in psychedelic psychometrics has been criticised on conceptual and cultural grounds. Stocker and colleagues set out to test whether mystical oneness is empirically associated with ego disintegration, renewal, and luminous light in controlled psychedelic studies. They also aimed to examine whether these experiences show dose-dependent changes across low, moderate, and high psychedelic doses, and whether distress is related to these constructs. The study uses the Psychedelic Experience Scale 100 (PES100) in pooled healthy-volunteer data from placebo-controlled and other controlled studies at two research sites. The work is presented as an exploratory psychometric analysis intended to refine how psychedelic experiences are measured, and to assess whether mystical dynamics may be a meaningful structure relevant to psychedelic-assisted therapy.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topic
- Authors
- APA Citation
Stocker, K., Hartmann, M., Barrett, F. S., Richards, W., Sepeda, N. D., Straumann, I., Klaiber, A., Vogt, S. B., Erne, L., Ley, L., Becker, A. M., Vizeli, P., Holze, F., & Liechti, M. E. (2026). Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies. Religion, Brain & Behavior, 1-16. https://doi.org/10.1080/2153599X.2026.2635353
References (25)
Papers cited by this study that are also in Blossom
Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Becker, A. M., Holze, F., Grandinett, T. et al. · Clinical Pharmacology and Therapeutics (2021)
Becker, A. M., Klaiber, A., Holze, F. et al. · International Journal of Neuropsychopharmacology (2022)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Show all 25 referencesShow fewer
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Holze, F., Gasser, P., Müller, F. et al. · Biological Psychiatry (2023)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)
Klaiber, A., Schmid, Y., Becker, A. M. et al. · Translational Psychiatry (2024)
Ley, L., Holze, F., Arikci, D. et al. · Neuropsychopharmacology (2023)
Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Mosurinjohn, S., Roseman, L., Girn, M. · Frontiers in Psychiatry (2023)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)
Straumann, I., Ley, L., Holze, F. et al. · Neuropsychopharmacology (2023)
Vogt, S. B., Ley, L., Erne, L. et al. · Translational Psychiatry (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.